Drug Trial Radar · NCT05695781
Assessment of the Safety and Efficacy of BRM421 Ophthalmic Solutions in Dry Eye Subjects.
Last checked: Nov 19, 2026Latest source record: Jul 11, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
740
Actual
Start
Feb 27, 2023
Primary completion
Dec 30, 2023
Study completion Mar 30, 2024
Sponsor
- Lead sponsor
- BRIM Biotechnology Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 25, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to compare the safety and efficacy of BRM421 OS to vehicle for the treatment of the signs and symptoms of dry eye disease.
Conditions
- Dry Eye Disease
Interventions
BRM421 Ophthalmic SolutionDrug
A topical drop of BRM421 ophthalmic solution.
VehicleDrug
A topical drop of vehicle (minus active) ophthalmic solution.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Ocular Sign: Change From Baseline in Total Corneal Fluorescein Staining ScoreTime frame: 1-2 weeks
- Ocular Symptom: Change From Baseline in Visual Analog Scale (VAS)Time frame: 1-2 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Andover Eye Associates
Warwick, Rhode Island
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.